Healthcare / Health Information ServicesTokyo
$1843.00
-12.00 (-0.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $778.9M · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$27.9B
P/E
25.9x
↑EV/EBITDA
15.3x
↑ROE
32.2%
↑Gross Margin
78.3%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+28.4%
FCF CAGR
+34.5%
FCF margin
33.9%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.39B · net income $1.09B · FCF $1.15B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.39B | $3.39B | $2.57B | $2.07B | $1.60B |
| Net Income | $1.09B | $1.09B | $808.3M | $612.9M | $449.6M |
| EBITDA | $1.65B | $1.65B | $1.22B | $970.6M | $714.5M |
| EPS | — | — | 53.02 | 40.22 | 32.54 |
| Gross Margin | 78.3% | 78.3% | 77.7% | 79.1% | 79.2% |
| Operating Margin | 45.3% | 45.3% | 44.2% | 43.9% | 43.2% |
| Net Margin | 32.1% | 32.1% | 31.4% | 29.6% | 28.0% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 0.05 | 0.09 |
| Current Ratio | 6.56 | 6.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.15B | $1.15B | $778.9M | $402.0M | $472.1M |
| Returns | |||||
| ROE | 32.2% | 32.2% | 33.6% | 36.3% | 40.7% |
| Valuation | |||||
| P/E | 25.87 | 25.87 | 37.06 | 47.79 | 54.24 |
| EV/EBITDA | 15.28 | 15.28 | 22.91 | 28.81 | 32.76 |
| P/B | 8.33 | 8.33 | 12.43 | 17.33 | 22.07 |
| Growth & Yield | |||||
| Revenue Growth | 31.9% | 31.9% | 24.3% | 29.1% | — |
| EPS Growth | — | — | 31.8% | 23.6% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.4%
Start / end P/E
n/dx → n/dx
EPS bridge
53.02 → n/d
Residual
-22.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.